Applying validated rare disease algorithms to millions of Electronic Health Records in a regulatory-compliant manner, uncovering at-risk or diagnosed individuals hidden in plain sight
Creating an interactive patient risk-assessment module for integration into your website, providing insights on undiagnosed consumers concerned about their risk level
ThinkGenetic, Inc. is an award-winning digital health company specializing in finding individuals at risk of rare and genetic conditions.
Leveraging validated algorithms and extensive expertise in rare diseases, ThinkGenetic offers digital solutions to detect patients for evaluation, treatment, and clinical trials, while ensuring compliance with important PHI (Protected Health Information) regulations.
The company serves clients in biopharma, research institutions, healthcare practice settings, and advocacy organizations. We empower our clients to uncover individuals who may be vulnerable and provide essential resources to support critical healthcare decisions using the power of AI technology.
ThinkGenetic’s unparalleled, masterclass level of knowledge and expertise provides the foundation to help our clients overcome challenges in rare diseases. Together, our results-oriented solutions, provide a robust library of research on our unique approach. This loop of refinement supports the continuous validation of our state-of-the-art proprietary algorithms.
“The project with ThinkGenetic has sparked significant interest within our organization. As a result, we have scheduled a wider, regional roll-out across our Growth & Emerging Markets Business Unit which spans almost 50 countries. Additionally, within the wider Takeda community, our global colleagues are considering its implementation in other countries and regions.”
Marie Gray, Regional Franchise Head Rare Metabolic Disease & Neuroscience Takeda
“Your entrepreneurial approach to leveraging genetic-sequencing data to proactively identify patients at risk for a rare condition has the potential to improve the quality of life for millions of patients and their families. I applaud and respect the drive and passion it takes to bring your idea to fruition. On behalf of rare disease patients around the world, thank you.”
Tim Walbert, chairman, president and chief executive officer, Horizon Therapeutics
“As a company committed to helping patients with rare genetic disorders, PTC Therapeutics is excited to partner with ThinkGenetic and GRN. Reaching the right diagnosis can be a long and difficult process for patients with rare diseases. We’re hopeful this partnership will help shorten that journey for patients, their families, and healthcare providers.”
Bruce Braughton, Senior Vice President and General Manager, PTC Therapeutics
Virginia Venture Partners, the equity investment program of Virginia Innovation Partnership Corporation (VIPC), today announced an investment in ThinkGenetic.
ThinkGenetic announces its participation at the 2023 National Society of Genetic Counselors (NSGC) Annual Meeting in Chicago, IL this October through the presentation of two poster sessions.
